Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
GLOBETECH PUBLISHING
JIB

Identification of Rare Mutation May Lead to Heart Repair Gene Therapy

By BiotechDaily International staff writers
Posted on 17 Mar 2014
Image: In the heart muscle cell above, the arrows show an early sign of replication (Photo courtesy of Johns Hopkins University).
Image: In the heart muscle cell above, the arrows show an early sign of replication (Photo courtesy of Johns Hopkins University).
Identification of the mutation responsible for an exceedingly rare type of heart defect in infants may pave the way for a gene therapy approach for regenerating adult heart tissue damaged by heart attack or disease.

Investigators at Johns Hopkins University (Baltimore, MD, USA) had been examining the hearts removed from two infant siblings during heart transplant surgery. Initial findings were that cells in the heart muscle (cardiomyocytes) were continuing to divide despite the fact that the infants had passed the age by which such cell division has normally terminated. The investigators established that the infants' genomes contained two abnormal copies of the ALMS1 gene. The same mutation was then found in five infant patients, including two sets of siblings, at the Hospital for Sick Children (Toronto, Canada).

The investigators reported in the March 4, 2014, online edition of the journal Nature Communications that the ALMS1 gene mutation caused a deficiency of the Alström protein that impaired the ability of the heart cells to stop dividing. In a genetically engineered mouse model, animals that lacked the ALMS1 gene displayed increased cardiomyocyte proliferation at two weeks postnatal compared with wild-type littermates. Furthermore, cultured cardiomyocytes divided abnormally after exposure to siRNA (short interfering RNA) that blocked expression of the ALMS1 gene.

“This study offers hope that we can someday find a way to restore the ability of heart cells to divide in response to injury and to help patients recover from many kinds of cardiac dysfunction,” said senior author Dr. Daniel P. Judge, associate professor of cardiology at Johns Hopkins University. “Things usually heal up well in many parts of the body through cell division, except in the heart and the brain. Although other work has generated a lot of excitement about the possibility of treatment with stem cells, our research offers an entirely different direction to pursue in finding ways to repair a damaged heart.”

“The children who helped us recognize the importance of this gene were born with a rare condition that leads to heart failure and many other problems, such as diabetes, obesity, blindness, and deafness,” said Dr. Judge. “Now we hope to apply these discoveries to help millions of others with heart disease.”

Related Links:

Johns Hopkins University
The Hospital for Sick Children
 


comments powered by Disqus

Channels

Drug Discovery

view channel
Image: A mouse mammary gland missing the tumor-suppressor p53 shows expression of ARF (green), now known for a backup role in protecting cells from becoming cancerous. If both p53 and ARF are mutated, the tumors that form are aggressive and may benefit from treatment with anti-inflammatory drugs called JAK inhibitors, currently prescribed for rheumatoid arthritis (Photo courtesy of Raleigh Kladney).

Anti-Inflammatory Drugs May Treat Some Aggressive Rumors

New research raises the possibility that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs used to treat rheumatoid arthritis. By studying triple-negative... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.